Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

MYGNBearishLegalnews

High materiality8/10

Myriad Genetics Faces Probe After Q2 Revenue Decline and Guidance Cut

Aug 13, 2026, 8:05 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Legal investigations add uncertainty and potential liability; combined with weak quarter and guidance, historically similar probes have led to sustained multiple contractions until clarity emerges (e.g., prior securities probes impacting mid-cap biotech names).

AI summary

What happened, with direct paths to the underlying reporting

Kirby McInerney LLP disclosed an investigation into Myriad Genetics regarding potential securities-law violations. Myriad reported a Q2 revenue of 190.7M, down 11% YoY with a 9% drop in average revenue per test and cut its full-year guidance to 770-790M, including an 11M impact from prior-period estimates. The stock fell about 47% to 2.86 as investors reassessed the fundamental and legal risk.

Q2 revenue 190.7M, down 11% YoY; full-year guidance cut to 770-790M.
Hereditary cancer testing revenue down 13% despite 8% volume rise; payer friction cited.
Stock plunged ~47% to $2.86 after results; management cites prior-period collection estimate changes.
Kirby McInerney LLP announces investigation into Myriad; no lawsuit filed yet.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Myriad Genetics Faces Probe After Q2 Revenue Decline and Guidance Cut

Myriad Genetics Faces Cost Restructuring As UnitedHealthcare Ends GeneSight Coverage, Appoints New CEO

Myriad (MYGN) Reports Q1 Earnings: What Key Metrics Have to Say